LS-P-AJAR: Phase 1 study of novel immunotherapy treatment for metastatic castration-resistant prostate cancer with a T cell engager targeting PSMA and CD3 (Janx007)
LS-P-EVOPAR: A Phase III study of novel selective PARP1 inhibitor (AZD5305) in combination with standard hormonal agents for patients newly diagnosed with metastatic castration-sensitive prostate cancer with or without DNA repair mutations.
LS-P-ASCERTAIN: Study of novel selective PARP1 inhibitor (AZD5305) alone or in combination with darolutamide given before radical prostatectomy for patients with unfavorable intermediate risk or high risk prostate cancer.
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation
